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Abstract. Few data regarding the use of Japanese encephalitis (JE) vaccine in clinical practice are available. We
identified 711 travelers at higher risk and 7,578 travelers at lower risk for JE who were seen at US Global TravEpiNet
sites from September of 2009 to August of 2012. Higher-risk travelers were younger than lower-risk travelers (median
age = 29 years versus 40 years, P < 0.001). Over 70% of higher-risk travelers neither received JE vaccine during the
clinic visit nor had been previously vaccinated. In the majority of these instances, clinicians determined that the
JE vaccine was not indicated for the higher-risk traveler, which contradicts current recommendations of the Advisory
Committee on Immunization Practices. Better understanding is needed of the clinical decision-making regarding
JE vaccine in US travel medicine practices.
BACKGROUND
Japanese encephalitis (JE) virus is a mosquito-borne
flavivirus that is endemic in much of Asia and parts of the
western Pacific. An estimated 70,000 JE cases occur per year;
the case-fatality ratio is 20–30%, and 30–50% of survivors
have neurologic or psychiatric sequelae.1–3 For travelers, the
risk of disease is generally low but varies with destination,
trip duration, season of travel, and planned activities.2 Fifty-
five travel-associated JE cases were reported in the litera-
ture during 1973–2008.4
The Advisory Committee on Immunization Practices (ACIP)
recommends JE vaccination for all travelers who plan to
spend 1 month or more in JE-endemic regions during the
transmission season. The ACIP further states that the vaccine
should be considered for short-term (< 1 month) travelers
going to rural areas whose itineraries or activities place them
at increased risk of JE virus exposure, short-term travelers
going to areas with known outbreaks, and short-term travelers
who are unsure of their itinerary.2 Two JE vaccines have been
available for use in the United States: an inactivated mouse
brain-derived vaccine (JE-VAX, Sanofi Pasteur, Swiftwater,
PA) and an inactivated Vero cell culture-derived vaccine
(IXIARO, Novartis Vaccines, Cambridge, MA).2 JE-VAX
was associated with rare but serious hypersensitivity and neu-
rologic adverse events.2 Production of JE-VAX was
discontinued in 2006, and limited supplies were available until
2011. IXIARO, which is given as a two-dose series adminis-
tered 28 days apart, was approved by the Food and Drug
Administration in March of 2009. Until 2013, IXIARO was
licensed for use only in people ages ³ 17 years.
Few data regarding the use of JE vaccine in clinical prac-
tice are available. A 2007 airport survey of US travelers to
Asia found that only 11% of higher-risk travelers (defined
as those traveling to JE-endemic areas for ³ 30 days or
spending more than one-half their trip in rural areas) had
received JE vaccine.5 Furthermore, 69% of these higher-risk
travelers who had visited a healthcare provider before their
trip indicated that JE vaccine had not been recommended
during the clinical encounter.
In this study, we describe the demographic characteristics
of US residents traveling to JE-endemic countries and evalu-
ate the current use of JE vaccine in a large consortium of
US clinical practices that provide pre-travel healthcare. We
focused particularly on the time period since the introduc-
tion of IXIARO.
METHODS
Global TravEpiNet clinics. Global TravEpiNet (GTEN)
is sponsored by the Centers for Disease Control and Pre-
vention (CDC), and it is a consortium of US clinical prac-
tices that provide pre-travel care to international travelers.6
GTEN sites are distributed across the US and include aca-
demic practices, healthcare consortia, health maintenance
organizations, pharmacy-based clinics, private practices, and
public health clinics. An institutional review board at each
participating site reviewed and approved the study.
Study population. We evaluated international travelers
seen at GTEN sites from September of 2009 to August of
2012. Clinicians collected data on travelers using a secure
internet tool. For each clinic visit associated with a unique
itinerary, travelers provided details about their medical his-
tory, destination countries, purpose of travel, geographic
type of travel (urban, rural, or both), planned activities,
planned accommodations, and duration and dates of travel.
Clinicians verified the information provided by travelers
and entered additional data on immunization history, health
advice provided, vaccines administered, and medications pre-
scribed during the pre-travel encounter. Clinicians were able
to review additional geographic details of the itinerary, such
as cities or regions visited within a destination country, but
these details were not captured further for analysis. If a
traveler had an indication for a vaccine according to ACIP
guidelines that were current at the time of the clinic visit but
the vaccine was not administered, the clinician was required
to provide a reason for not administering the vaccine; avail-
able options included pre-existing immunity, vaccine not
indicated, referred to primary care provider for vaccination,
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patient declined, medical contraindication, insufficient time,
or vaccine not available. Of note, IXIARO was in use
throughout the time period of this study; JE-VAX was
available only in limited supplies, and all doses had expired
by May of 2011.
Data analysis. For the purpose of this analysis, we consid-
ered the following countries to be endemic for JE in accor-
dance with the CDC definitions7: Bangladesh, Brunei, Burma/
Myanmar, Cambodia, China, India, Indonesia, Japan, Laos,
Malaysia, Nepal, Papua New Guinea, Philippines, South
Korea, Sri Lanka, Taiwan, Thailand, and Vietnam. Australia,
Bhutan, Mongolia, North Korea, Pakistan, Russia, Singapore,
Timor-Leste, and the Western Pacific Islands were excluded
from this analysis, because JE cases are very rare or JE risk
data are limited. Transmission seasons for each country were
defined according to the CDC.7 We limited our analysis to
travelers ages 17 years or older whose itineraries included
travel only to JE-endemic countries. Higher-risk travelers
were defined as those traveling for 30 days or longer during
transmission season and who were planning to visit a rural
setting. Lower-risk travelers were those traveling outside the
transmission season, traveling for fewer than 30 days, or only
visiting urban settings.
Data analyses were performed using Stata 12.0 (StataCorp,
College Station, TX). We used Somers’ D test and separate
random intercept logistic regressions with clinical site as the
random effect to evaluate bivariate measures of association.
We first performed a bivariate logistic regression analysis of
higher-risk travelers to examine the effect of various indi-
vidual variables on the likelihood that a clinician would deem
a JE vaccine as not indicated for a higher-risk traveler who
had not previously been vaccinated; the comparison group
was higher-risk travelers who received the vaccine. We exam-
ined variables included gender, duration of travel (days),
time until departure (³ 30 versus < 30 days from the clinic
visit), type of travel (rural versus urban/rural), purposes of
travel, and destination countries. In the interest of building a
parsimonious model, we included only variables that were
significant at a two-sided P value of 0.10 in our multivariable
random effects logistic regression model. Additionally, we
used a two-sided Student’s t test to examine differences in
JE vaccine administration rates between the first and last
years of the study.
RESULTS
During the time period of this study, 29,885 travelers
ages ³ 17 years were seen at GTEN clinics. The median
number of travelers seen at each clinic was 488 (interquartile
range = 215–1,691). Of 29,885 travelers, 8,289 (27.7%) were
planning to travel exclusively to one or more JE-endemic
countries, whereas another 2,166 (7.2%) were traveling to
JE-endemic countries along with other countries not endemic
for JE. For this analysis, we focused only on the former
group; we classified 711 (8.6%) as higher-risk travelers and
7,578 (91.4%) as lower-risk travelers (Table 1). Higher-risk
travelers were traveling for a median of 50 days (inter-
quartile range = 32–93 days), and lower-risk travelers were
traveling for a median of 14 days (interquartile range =
11–21 days). Higher-risk travelers were significantly younger
than lower-risk travelers (median age = 29 years versus
40 years, P < 0.001). Leisure was the most frequent pur-
pose of travel for both categories of travelers. Travel for
research/education, to visit friends and relatives (VFR), and
for humanitarian service work represented a greater pro-
portion of higher-risk travel than lower-risk travel, and busi-
ness travel represented a greater proportion of lower-risk
travel. Higher-risk travelers sought pre-travel healthcare
earlier than lower-risk travelers (median = 28 days versus
23 days before departure, P = 0.004).
Of higher-risk travelers, 11 (1.5%) had received JE vac-
cine within the previous 2 years, whereas an additional
Table 1
Demographic and travel-related characteristics of higher and lower JE risk travelers
Higher-risk travelers (N = 711) Lower-risk travelers (N = 7,578)
P value*N Percent N Percent
Age (years) < 0.001
17–49 569 80.0 5,079 67.0
50–64 103 14.5 1,728 22.8
³ 65 39 5.5 771 10.2
Gender (female) 400 56.3 3,968 52.4 0.059
Purpose of travel†
Leisure 351 49.4 4,468 59.0 < 0.001
Research/education 169 23.8 611 8.1 < 0.001
Business 149 21.0 2,174 28.7 0.003
VFR 144 20.3 773 10.2 < 0.001
Humanitarian service work‡ 132 18.6 602 7.9 < 0.001
Other§ 11 1.6 150 2.0 0.193
Days to departure at clinic visit 0.002
0–13 183 25.7 2,313 30.5
14–20 89 12.5 1,072 14.1
21–27 83 11.7 914 12.1
³ 28 356 50.1 3,279 43.3
JE vaccination status < 0.001
Vaccinated within previous 2 years 11 1.5 28 0.4
Received vaccine for this itinerary 188 26.8 300 4.0
Not vaccinated 512 71.6 7,250 95.7
*P value determined using a Somers’ D-derived test adjusting for clustering among clinical sites.
†Travelers with multiple purposes of travel were included more than one time; therefore, totals sum to > 100%.
‡Humanitarian service work includes medical service work, non-medical service work, and missionary work.
§Other reasons include travel to attend a mass gathering, for military purposes, to adopt, or for an explicitly stated other reason.
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188 (26.4%) were administered the JE vaccine at their
pre-travel visit (Table 1). Of lower-risk travelers, 28 (0.4%)
had been vaccinated within the previous 2 years, and
300 (4.0%) were administered the JE vaccine at the pre-
travel visit.
Administration of JE vaccine at GTEN clinics increased
during the time period of the study. Overall, 7.2% of all
travelers who were exclusively visiting JE-endemic coun-
tries received the JE vaccine in the first year of the study
(September of 2009 to August of 2010) compared with
8.6% of such travelers in the final year (September of 2011
to August of 2012, P = 0.04). The proportion of travelers
to JE-endemic countries who were deemed higher -risk
according to our study criteria did not significantly change
over the time period of the study (8.9% in the first year
versus 8.3% in the final year, P = 0.42).
Figure 1 shows the countries visited by higher-risk trav-
elers. Overall, India was the most common destination
country for both higher- and lower-risk travelers. The top
five destination countries were the same for both higher-
and lower-risk travelers and included India (48% of higher-
risk travelers and 40% of lower-risk travelers), Thailand
(17% of higher-risk travelers and 20% of lower-risk trav-
elers), Cambodia (14% of higher-risk travelers and 18%
of lower-risk travelers), Vietnam (13% of both higher-risk
and lower-risk travelers), and China (11% of higher-risk
travelers and 12% of lower-risk travelers).
In total, 512 (72.0%) higher-risk travelers neither received
JE vaccine during the clinic visit nor had been previously
vaccinated (Table 1). Table 2 shows the reasons that clini-
cians provided for not administering JE vaccine to these
higher-risk travelers. In the majority of instances (55.1%),
clinicians stated that JE vaccine was not indicated for the
higher-risk traveler; 116 (22.7%) travelers declined the
vaccine, and 85 (16.6%) travelers had insufficient time
(< 28 days) to complete the JE vaccine series before departure.
Thirty (35.3%) of eighty-five travelers with insufficient time
to complete the JE vaccine series were seen by a clinician
14–27 days before their departure date.
We performed a multivariable analysis to identify factors
associated with a clinician’s determination that the JE vaccine
Figure 1. Frequency of visits to JE-endemic countries by higher-risk travelers. Travelers who visited more than one country are included
more than one time; 10 travelers to South Korea (8) and Taiwan (2) were excluded because of missing data.
Table 2
Reasons provided by clinicians for not administering the JE vaccine
to higher-risk travelers with no previous JE vaccination history
(N = 512)
Reason Number Percent
Vaccine not indicated 282 55.1
Patient declined 116 22.7
Insufficient time 85 16.6
Vaccine not available 11 2.1
Referred to other provider 5 1.0
Medical contraindication 3 0.6
Unknown* 10 2.0
*Data were missing for 10 higher-risk travelers to South Korea (8) and Taiwan (2).
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was not indicated for a higher-risk traveler. Clinicians were
more likely to consider JE vaccine to not be indicated for
VFR travelers and travelers to India (Table 3). Because not
all regions of India are endemic for JE, we performed the
same multivariable analysis, but we excluded travelers to
India; this change did not affect the findings.
DISCUSSION
Travel to Asia has been increasing in recent decades,
placing more travelers at potential risk for JE.8 This work
is the first description of the use of JE vaccine in a large
clinical consortium in the United States since the intro-
duction of IXIARO in 2009. Approximately one-quarter of
all travelers in our study were adults who were visiting
countries that are endemic or partially endemic for JE.
Most of these travelers were considered to be at lower risk
for JE according to our classification scheme.
We defined travelers as being at higher risk for JE if they
were traveling long-term (30 days or longer) to JE-endemic
countries during the transmission season and planning to
visit rural areas. ACIP recommends JE vaccination for
travelers who plan to spend ³ 1 month in endemic areas.2
However, we found that only slightly more than one-quarter
of these higher-risk travelers received JE vaccination in
association with their clinic visit. In the majority of cases,
JE vaccine was not administered because the clinician
reported that the vaccine was not indicated. Clinicians were
more likely to consider JE vaccine to not be indicated for
VFR travelers and travelers to India.
GTEN sites care for a large number of international
travelers, and we speculate that the providers in this study
are likely to be familiar with ACIP recommendations for
JE vaccine use. This suggests that factors other than lack of
awareness of ACIP recommendations influenced their clini-
cal decision-making. Healthcare providers must consider a
number of factors when deciding whether to administer a
travel-related vaccine, including the details of the traveler’s
itinerary and risk of exposure to disease, vaccine cost, mor-
bidity and mortality of the disease, and potential adverse
events after vaccination.9 Although JE can be a fatal disease
with high morbidity, the risk of infection for travelers is
low.10,11 A review of published cases of JE in travelers dur-
ing 1973–2008 estimated the incidence rate for travelers from
non-endemic areas to be 0.2 cases per million.4 Although
current ACIP recommendations are formulated based on
these low-incidence rate estimates, clinicians who chose not
to administer JE vaccine may have considered this low infec-
tion risk in their decision-making. Alternatively, clinicians
might have considered the JE vaccine to be too costly, and
therefore deemed it not indicated. Country-specific details
of the traveler’s itinerary that were not included in our
analysis may also have influenced the clinicians’ risk assess-
ments. Lastly, clinicians may have hesitated to administer
JE vaccines given the adverse event profile that was previ-
ously associated with JE-VAX. The temporal increase in
use of JE vaccine observed in our study suggests that the
improved tolerability of IXIARO or increased awareness
associated with the licensure of a new vaccine may have
influenced clinical decisions.
IXIARO is administered in two doses separated by
28 days.2 For approximately one-sixth of higher-risk trav-
elers who did not receive JE vaccine, the clinician indicated
that there was insufficient time to complete the vaccine
series before departure. A sizable number of these travelers
had clinic appointments 14–27 days before departure. Avail-
ability of a more accelerated JE vaccine schedule might,
therefore, increase the number of travelers who are able to
receive the vaccine before departure.
Our study has some limitations. Although GTEN is the
largest consortium of clinics providing pre-travel care in the
United States, GTEN sites may not be representative of
all travel medicine practices. GTEN does not collect data
regarding clinician demographics, educational background,
or years in practice, and hence, we cannot relate clinician-
specific factors to decision-making regarding JE vaccine
administration. We also did not collect details on the ratio-
nale behind clinical decision-making about JE vaccine, and
hence, we cannot determine why clinicians diverged from
ACIP recommendations for use of JE vaccine. An in-depth
survey of clinician knowledge, attitudes, and practices regard-
ing JE vaccine would be useful for exploring this area.
In summary, we found that many travelers whose itineraries
placed them in a category for which JE vaccine is clearly
recommended by the ACIP were not offered the vaccine by
clinicians, who deemed the vaccine to not be indicated. The
failure of clinicians to adhere to practice guidelines is an area
in need of additional research.12 Clear and accurate informa-
tion about travel-related disease risks and prevention options
needs to be available to healthcare providers and the public.
Web-based decision support tools for patients have been use-
ful for improving uptake of other vaccines, such as the measles-
mumps-rubella vaccine.13 A better understanding of JE
vaccine administration practices since the advent of IXIARO
is necessary, with a particular focus on understanding why
clinical practice differs from current guidelines.
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